Abstract:Liposomal spherical nucleic acids (L-SNAs) show significant promise as cancer immunotherapeutics. L-SNAs are highly modular nanoscale assemblies defined by a dense, upright radial arrangement of oligonucleotides around a liposomal core. Herein, we establish a set of L-SNA design rules by studying the biological and immunological properties of L-SNAs as a function of liposome composition. To achieve this, we synthesized liposomes where the lipid phosphatidylcholine headgroup was held constant, while the diacyl lipid tail chain length and degree of saturation were varied, using either 1,2-dioleylphosphatidylcholine (DOPC), 1,2-dimyristoyl-phosphatidylcholine (DMPC), 1,2-dipalmitoylphosphatidylcholine (DPPC), or 1,2-distearoyl-phosphatidylcholine (DSPC). These studies show that the identity of the constituent lipid dictates the DNA loading, cellular uptake, serum stability, in vitro immunostimulatory activity, and in vivo lymph node accumulation of the L-SNA. Furthermore, in the 4T1 mouse model of triple-negative breast cancer (TNBC), the subcutaneous administration of immunostimulatory L-SNAs synthesized with DPPC significantly decreases the production of lung metastases and delays tumor growth as compared to L-SNAs synthesized using DOPC, due to the enhanced stability of L-SNAs synthesized with DPPC over those synthesized with DOPC. Moreover, the inclusion of cell lysates derived from Py8119 TNBC cells as antigen sources in L-SNAs leads to a significant increase in antitumor efficacy in the Py8119 model when lysates are encapsulated in the cores of L-SNAs synthesized with DPPC rather than DOPC, presumably due to increased codelivery of adjuvant and antigen to dendritic cells in vivo. This difference is further amplified when using lysates from oxidized Py8119 cells as a more potent antigen source, revealing synergy between the lysate preparation method and liposome composition in synthesizing immunotherapeutic L-SNAs. Together, this work shows that the biological properties and immunomodulatory activity of L-SNAs can be modulated by exchanging liposome components, providing another handle for the rational design of nanoscale immunotherapeutics.The molecular identity of the lipids that comprise liposomal spherical nucleic acids modulates their biological properties and provides a handle for their rational design as cancer immunotherapeutics.This article has not yet been cited by other publications.

Liposome-aided Metabolic Engineering of Tumor Surface Immunogenicity

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Redirecting Immunity Via Covalently Incorporated Immunogenic Sialic Acid on the Tumor Cell Surface.

Biomimetic Metallacage Nanoparticles with Aggregation-Induced Emission for NIR-II Fluorescence Imaging-Guided Synergistic Immuno-Phototherapy of Tumors

Generation of Triacyl Lipopeptide-Modified Glycoproteins by Metabolic Glycoengineering As the Neoantigen to Boost Anti-Tumor Immune Response.

Tumor Cell Surface Modification with Immuno-Amplified Nanoparticles to Enhance Cancer Immunotherapy

Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy

Engineered Bacteria-Mediated Augmentation of Sialoglycan Degradation Strategy and Immunogenic Chemotherapy to Boost Effective Cancer Therapy

Impact of Liposomal Spherical Nucleic Acid Structure on Immunotherapeutic Function

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immuno‐Killing

Disrupting the Interplay Between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer.

Tumor Suppression Via Diverting Intracellular Sialylation with Multifunctional Nanoparticles.

Sialidase-Conjugated “nanoniche” for Efficient Immune Checkpoint Blockade Therapy

Tumor-Associated Enzyme-Activatable Spherical Nucleic Acids.

Solid Tumor Target-Immunotherapy with Novel Biomimetic Immuno- Chemotherapy Composite Mesoporous Silica Nanoparticles Coated by the CD80 Modified Cell Membranes

Ultra‐Galactocation to Sialic Acid on Tumor Cells with A Penta‐Functional Dendritic Probe for Enhanced Immune‐Killing

Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo‐immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment

Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy

Surface-Layer Protein-Enhanced Immunotherapy Based on Cell Membrane-Coated Nanoparticles for the Effective Inhibition of Tumor Growth and Metastasis.